Overview

• evoCAST, a CRISPR-associated transposase system, enables precise insertion of complete genes into targeted genomic locations without breaking chromosomes.
• The system, developed by teams at Columbia University and the Broad Institute, utilizes PACE to enhance editing efficiency to 30–40%, a significant improvement over earlier versions.
• This advancement could simplify treatment for genetic disorders like cystic fibrosis by enabling single therapies for diverse mutations.
• Researchers are now testing evoCAST in relevant model systems and working to further refine its components for greater efficiency.
• A major hurdle remains in delivering evoCAST and its genetic payloads effectively into target cells or tissues for clinical application.